Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 2/20 | 0.55 |
| ▸ | PRKCA | P17252 | 2/20 | 0.55 |
| ▸ | BCDIN3D | Q7Z5W3 | 3/20 | 0.53 |
| ▸ | SYK | P43405 | 4/20 | 0.50 |
| ▸ | ZAP70 | P43403 | 3/20 | 0.50 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.50 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | ITK | Q08881 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | IDH2 | P48735 | 3/20 | 0.44 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | FLT4 | P35916 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23696 | 0.87 | AURKA (0.52) | CDK1PRKCAAURKAKDM4EIDH2 | |
| SCHEMBL15207316 | 0.86 | KDM4E (0.44) | CDK1PRKCABCDIN3DSYKAURKA | |
| SCHEMBL15207975 | 0.86 | SYK (0.46) | CDK1PRKCABCDIN3DSYKAURKA | |
| SCHEMBL23569 | 0.85 | ZAP70 (0.48) | CDK1PRKCABCDIN3DSYKZAP70 | |
| SCHEMBL23189 | 0.84 | IDH2 (0.57) | AURKAKDM4EIDH2JAK2PTK2 | |
| SCHEMBL24629 | 0.84 | IDH2 (0.57) | AURKAKDM4EIDH2JAK2PTK2 | |
| SCHEMBL25084 | 0.84 | JAK2 (0.44) | CDK1PRKCABCDIN3DSYKZAP70 | |
| SCHEMBL24074 | 0.83 | JAK2 (0.48) | IDH2JAK2PTK2KDRJAK3 | |
| SCHEMBL24502 | 0.82 | SLC6A2 (0.51) | JAK2PTK2JAK3LMNAMAPT | |
| SCHEMBL23674 | 0.82 | IDH2 (0.47) | CDK1PRKCABCDIN3DAURKAIDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | claimed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | claimed |
| EP-2609098-B1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-07-13 | — | — | EP | disclosed |
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
| WO-2012025186-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | SYK, IRAK1, ZAP70 | CDK1 214/4885PRKCA 758/4885BCDIN3D 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.